Most medications used for schizophrenia are in the
family. The atypical antipsychotics are so called because they are chemically quite different.
They appear to cause fewer side effects than the phenothiazine drugs
Medications in this family include:
The herb St. John’s wort might reduce levels of these medications in the blood.1
This could lead to an increase in the severity of psychotic symptoms.
Perhaps even more dangerously, if medication levels are adjusted for an individual already taking St. John’s wort, stopping the herb could cause these levels to rise, potentially causing dangerous toxic symptoms.
A few studies suggest that the amino acid glycine may augment the action of phenothiazine antipsychotic drugs. It might also augment the action of olanzapine and risperidone, but whether it augments or decreases the effectiveness of clozapine remains unclear.3-7
article for a more detailed discussion of this subject.
Highly preliminary evidence suggests that ginkgo might reduce the side effects and increase the efficacy of various antipsychotic medications, including atypical antipsychotic drugs.2
De Smet PA and Touw DJ. Safety of St. John's wort.
Liu P, Luo HC, Shen YC, et al. Combined use of
extracts on the efficacy and adverse reactions of various antipsychotics [translated from Chinese].
Chin J Clin Pharmacol.
Heresco-Levy U, Ermilov M, Lichtenberg P, et al. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia.
Potkin SG, Jin Y, Bunney BG, et al. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.
Am J Psychiatry. 1999;156:145–147.
Evins AE, Fitzgerald SM, Wine L, et al. Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Am J Psychiatry. 2000;157:826-828.
Diaz P, Bhaskara S, Dursun SM, et al. Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results.
J Clin Psychopharmacol.
Buchanan RW, Javitt DC, Marder SR, et al. The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Am J Psychiatry.
Last reviewed August 2013 by EBSCO CAM Review Board
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.